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Summary
Background Magnetic resonance enterography (MRE) and ultrasound are used to image Crohn’s disease, but their 
comparative accuracy for assessing disease extent and activity is not known with certainty. Therefore, we did a 
multicentre trial to address this issue.
Methods We recruited patients from eight UK hospitals. Eligible patients were 16 years or older, with newly diagnosed 
Crohn’s disease or with established disease and suspected relapse. Consecutive patients had MRE and ultrasound in 
addition to standard investigations. Discrepancy between MRE and ultrasound for the presence of small bowel 
disease triggered an additional investigation, if not already available. The primary outcome was difference in per-
patient sensitivity for small bowel disease extent (correct identification and segmental localisation) against a construct 
reference standard (panel diagnosis). This trial is registered with the International Standard Randomised Controlled 
Trial, number ISRCTN03982913, and has been completed.
Findings 284 patients completed the trial (133 in the newly diagnosed group, 151 in the relapse group). Based on the 
reference standard, 233 (82%) patients had small bowel Crohn’s disease. The sensitivity of MRE for small bowel 
disease extent (80% [95% CI 72–86]) and presence (97% [91–99]) were significantly greater than that of ultrasound 
(70% [62–78] for disease extent, 92% [84–96] for disease presence); a 10% (95% CI 1–18; p=0·027) difference for 
extent, and 5% (1–9; p=0·025) difference for presence. The specificity of MRE for small bowel disease extent (95% 
[85–98]) was significantly greater than that of ultrasound (81% [64–91]); a difference of 14% (1–27; p=0·039). The 
specificity for small bowel disease presence was 96% (95% CI 86–99) with MRE and 84% (65–94) with ultrasound 
(difference 12% [0–25]; p=0·054). There were no serious adverse events.
Interpretation Both MRE and ultrasound have high sensitivity for detecting small bowel disease presence and both 
are valid first-line investigations, and viable alternatives to ileocolonoscopy. However, in a national health service 
setting, MRE is generally the preferred radiological investigation when available because its sensitivity and specificity 
exceed ultrasound significantly. 
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Introduction
Small bowel imaging is fundamental for comprehensive 
phenotyping of Crohn’s disease and essential to direct 
therapeutic strategy.1 Barium fluoroscopy has long been 
the bedrock of small bowel investigation, providing 
detailed mucosal assessment.2 However, in the past 
5–10 years enthusiasm has dwindled, and barium 
fluoroscopy is being increasingly replaced by cross-
sectional imaging, namely computed tomography 
enterography (CTE), magnetic resonance enterography 
(MRE), and ultra sound. Advocates of cross-sectional 
imaging stress that these techniques assess the bowel 
wall and beyond, complementing endoscopic 
visualisation. As barium fluoroscopy is abandoned, 
dissemination of the various cross-sectional imaging 
technologies has been relatively uncontrolled, despite a 
paucity of supportive data from methodologically sound 
prospective multicentre studies. This scarcity of robust 
evidence is concerning given the pivotal role assumed by 
small bowel imaging over the lifetime of patients with 
Crohn’s disease.
Of the available modalities, MRE and ultrasound are 
preferred3 since they avoid irradiating generally young 
patients who require repeat imaging.4 Enteric ultrasound 
is longer established,5 requires little patient preparation, 
and the technology is widely available. However, 
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questions remain over accuracy, particularly in the 
proximal bowel and deep pelvis,6 and perceived 
interobserver variability.7 Conversely, MRE is a newer 
innovation,8 requires oral contrast and access to advanced 
technology imaging platforms, which are comparatively 
restricted in many health-care settings.
Although meta-analyses6,9–20 suggest that MRE and 
ultrasound have similar accuracy for diagnosing and 
staging Crohn’s disease, the primary literature is of 
questionable quality. Most studies17,20,21 are small and 
done in a single centre, and few compare tests directly in 
the same patients, despite this being advocated as an 
optimal method for diagnostic accuracy studies.22 For 
example, in their meta-analysis,15 Greenup and colleagues 
found that just one of 33 included studies compared 
MRE and ultrasound directly in the same patients. 
Additionally, very few studies use a construct reference 
standard model (panel diagnosis), which incorporates 
concepts of diagnostic test validation based on patient 
outcomes and has distinct methodological advantages 
when a single reference standard is elusive.23
To redress this, we did a multicentre trial to elucidate 
and then directly compare the diagnostic accuracy of 
MRE and ultrasound for small bowel Crohn’s disease 
against a construct reference standard incorporating 
patient follow-up. To reflect normal clinical practice, we 
recruited both newly diagnosed patients and those with 
established disease in whom luminal relapse was 
suspected.
Methods
Study design and participants
The METRIC study is a multicentre trial that compares 
the diagnostic accuracy of MRE and enteric ultrasound 
for the presence, extent, and activity of small bowel 
Crohn’s disease in newly diagnosed patients or patients 
with established disease and suspected relapse. We 
achieved ethics committee approval in September, 2013 
(13/SC/0394). The trial was supervised by University 
College London’s Comprehensive Clinical Trials Unit 
and overseen by independent Data Monitoring and Trial 
Steering Committees. All patients recruited gave written 
informed consent. The full trial protocol has been 
published,24 and can be found online.
We recruited patients from eight UK National Health 
Service (NHS) teaching and general hospitals, 
For the full trial protocol see 
http://www.ucl.ac.uk/cctu/
research-areas/gastroenterology/
metric
Research in context
Evidence before this study
Cross-sectional imaging is fundamental for diagnosis and 
management of Crohn’s disease and is replacing barium 
fluoroscopic techniques, which have been the bedrock of small 
bowel imaging for many years. However, dissemination of 
cross-sectional imaging has occurred despite a paucity of 
supportive data from prospective multicentre studies recruiting 
consecutive and unselected patients. Emphasis is placed on 
magnetic resonance enterography (MRE) and enteric 
ultrasound because they avoid ionising radiation. Clinical 
uptake of ultrasound has been hampered by concerns over 
diagnostic accuracy and perceived high levels of interobserver 
variation. MRE is a newer innovation that necessitates access to 
comparatively restricted advanced technology imaging 
platforms. We searched PubMed and Embase in January, 2018, 
for articles published between Jan 1, 1990, and Jan 1, 2018, 
without language restriction. We used MeSH and full-text 
search for “Crohn’s disease”, “magnetic resonance imaging”, 
“ultrasound”, and “diagnostic accuracy”. We retrieved primary 
literature but we placed emphasis on meta-analyses and 
systematic reviews using appropriate filters. We found several 
meta-analyses, which generally suggest that MRE and 
ultrasound have similar sensitivity for detection and activity 
assessment of small bowel Crohn’s disease. However, the 
primary literature has limitations. Most studies are small, 
single-centre explanatory trials, recruiting fewer than 
50 patients. Tests are rarely compared in the same patients, 
introducing bias caused by differences between patients and 
disease phenotype, and use inconsistent reference standards. 
For example, in one meta-analysis, just one of 33 included 
studies compared MRE and ultrasound directly in the same 
patients. Many studies also rate poorly on the Quality 
Assessment of Diagnostic Accuracy Studies tool.
Added value of this study
To our knowledge, this study is the largest prospective 
multicentre trial to date comparing the diagnostic accuracy of 
MRE and ultrasound for the presence, extent, and activity of 
enteric Crohn’s disease, with the use of a construct reference 
standard incorporating 6 months of patient follow-up. We used 
a pragmatic trial design to better assess test performance in 
routine clinical practice, and we used the preferred method for 
diagnostic accuracy studies by comparing tests in the same 
patients. Both tests achieved high accuracy for detecting and 
localising small bowel Crohn’s disease, but sensitivity and 
specificity for small bowel disease presence and extent were 
significantly greater for MRE than for ultrasound.
Implications of all the available evidence
Both ultrasound and MRE achieve high diagnostic accuracy for 
the extent and activity of small bowel Crohn’s disease in newly 
diagnosed patients and those who have relapsed. Although 
both tests are valid first-line investigations, MRE is generally 
the preferred radiological investigation when available because 
its sensitivity and specificity exceed ultrasound significantly 
when tested in a prospective multicentre trial setting. Future 
research should investigate the role of cross-sectional imaging 
in patients with non-specific abdominal symptoms without an 
established diagnosis of Crohn’s disease, and the 
complementary role of MRE and ultrasound in targeted 
follow-up of patients with Crohn’s disease with an established 
disease phenotype. 
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representative of institutions likely to implement MRE 
and ultrasound for patient management (appendix p 1). 
All sites had an established inflammatory bowel disease 
service and were already doing MRE and ultrasound as 
part of usual clinical practice. 
Patients were eligible for the newly diagnosed group 
if they had been diagnosed with Crohn’s disease in 
the 3 months preceding recruitment on the basis of 
conventional diagnostic criteria, or when Crohn’s disease 
was strongly suspected on the basis of imaging or 
endoscopic features but pending final diagnosis. Eligible 
patients had already had colonoscopy or were awaiting it 
at recruitment. Patients in whom the final diagnosis was 
not Crohn’s disease were subsequently excluded. 
Patients were eligible for the suspected luminal relapse 
group if they had established Crohn’s disease (>3 months) 
and there was a strong clinical suspicion of luminal 
relapse based on either objective markers of inflammatory 
activity (C-reactive protein [CRP] concentration >8 mg/L 
or faecal calprotectin concentration >100 g/g), 
symptoms suggestive of luminal stenosis (including 
obstructive symptoms, such as colicky abdominal pain, 
vomiting), or abnormal endoscopy. Eligible patients for 
both groups were aged 16 years or older. Patients were 
ineligible if they were pregnant or if they had contra-
indications to MRI. Those with psychiatric or other 
disorders who were unable to give informed consent 
were also excluded, as were those with evidence of severe 
or uncontrolled systemic disease. Patients in the newly 
diagnosed group were excluded if they had surgical 
resection before colonoscopy. 
Members of the local research team identified suitable 
patients from outpatient clinics, multidisciplinary team 
meetings, and inpatient wards, and they took informed 
consent from consecutive, unselected, eligible patients. 
A screening log detailed all approached patients and 
reasons for non-participation, if applicable. We collated 
patient demographics and clinical data (eg, age, sex, 
Montreal classification [relapse group only], disease or 
symptom duration, medication, and surgical history).
Procedures
Patients had MRE and ultrasound in addition to any 
other enteric imaging or endoscopic investigations done 
during their usual clinical care. 
MRE was done according to local standard clinical 
protocols (including the choice of oral contrast agent) 
on either 1·5 T or 3 T MRI platforms. We acquired a 
minimum dataset of sequences (appendix p 2). Ultrasound 
was done by radiologists or sonographers using standard 
platforms and both curvilinear and high-resolution probes, 
without oral or intravenous contrast agents (appendix p 3). 
Across all sites, 28 practitioners interpreted the MRE 
and ultrasound studies (27 radiologists and 1 sonographer). 
Eight radiologists interpreted MRE only, three performed 
and interpreted ultrasound only, and 16 performed 
and interpreted ultrasound and interpreted MRE. All 
radiologists were affiliated with the British Society of 
Gastrointestinal and Abdominal Radiology, with declared 
subspecialty interest in gastrointestinal radiology, and had 
completed the Fellowship of the Royal College of 
Radiologists, with at least 1 year of subspecialty training in 
gastrointestinal radiology. The sonographer had received 
formal training according to their sites’ local policies, was 
doing enteric ultrasound routinely, and had 20 years of 
experience. Radiologists interpreting MRE had a median 
of 10 years (IQR 6–11) of experience, and practitioners 
interpreting ultrasound had a median of 8 years (4–11) of 
experience. The median number of examinations done 
per month at each recruitment site during the conduct of 
the trial was 30 examinations (20–45) for MRE and 
25 examinations (12–40) for ultrasound. Before trial 
commencement, we held a 2-day hands-on workshop for 
investigators to standardise ultrasound technique and 
agree on description of enteric findings. 
MRE and ultrasound were interpreted by two different 
practitioners, each masked to the findings of the other, 
and masked to all other imaging, endoscopic, and clinical 
data except the group to which the patient was recruited 
(ie, newly diagnosed or relapse) and surgical history 
(since this information would normally be provided on 
clinical requests). Using case report forms, practitioners 
noted the presence and activity of Crohn’s disease in the 
small bowel and colon, together with any extraenteric 
complications, using established criteria (appendix p 4).6,16,25 
The segmental location of any disease was also recorded, 
using standard definitions;24 disease sites separated by 
more than 3 cm of normal bowel within a particular 
segment were recorded separately. Diagnostic confidence 
for disease presence was scored from 1 to 6, grouped into 
normal (levels 1–2), equivocal (levels 3–4), and abnormal 
(levels 5–6). A clinical report was then generated as per 
usual clinical practice. 
Members of the local research team collected the 
findings of all other small bowel imaging or endoscopies 
done as part of usual care. These tests were done and 
interpreted according to usual clinical practice at local 
sites, without masking. A case report form recorded 
colonoscopic findings specifically. 
For cases in which MRE and ultrasound had a 
discrepancy for the presence or location of small bowel 
disease, we did an arbiter small bowel investigation if 
patients had not already had additional small bowel 
imaging as part of usual care. We defined discrepancy as 
terminal ileal disease reported on either MRE or ultrasound 
in the absence of endoscopic visualisation, or disease 
reported in the small bowel upstream of the terminal 
ileum on either MRE or ultrasound. The nature of the 
additional test was left to local discretion and could include, 
for example, barium follow through, CTE, or capsule 
endoscopy. We also permitted repeat, targeted, and 
unmasked MRE or ultrasound to resolve discrepancies.
Where possible, we collected CRP concentration, 
calprotectin concentration, and the Harvey Bradshaw 
See Online for appendix
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index at recruitment and repeated between 10 and 
20 weeks later. We asked patients if they found MRE and 
ultrasound acceptable and which test attribute they 
considered to be the most important.  
We used the construct reference standard model 
(panel diagnosis), incorporating the concept of clinical 
test validation—ie, whether test results are meaningful 
in practice.23 Specifically, we followed patients’ clinical 
course for 6 months to assess the effect of MRE and 
ultrasound findings on clinical decision making and 
patient outcomes. Each recruitment site convened a 
series of consensus panels consisting of at least one 
local gastroenterologist and two radiologists (one local 
and one from another site); a histopathologist was 
available if required and a member of the trial 
management group attended to ensure uniformity of 
process. For each patient, the panel considered the 
images and results of all small bowel investigations 
(including MRE and ultrasound) and all additional 
information accrued over the follow-up period, 
including endoscopies, surgical findings, histopathology, 
Harvey Bradshaw index, CRP concentration, 
calprotectin concentration (and changes thereof), and 
clinical course. The panel recorded its opinion as to 
whether small bowel or colonic Crohn’s disease was 
present, and, if so, whether disease was active. All panel 
decisions were recorded as present or absent, active or 
inactive, with no option of an indeterminate outcome. 
Disease could only be categorised as active if at least one 
objective marker was present (ulceration as seen at 
endoscopy, measured CRP concentration >8 mg/L, 
measured calprotectin concen tration >250 g/g, 
histopathological evidence of acute inflammation based 
on a biopsy sample or surgery within 2 months of trial 
imaging). 
Outcomes
The primary outcome was the per-patient difference in 
sensitivity between MRE and ultrasound for correct 
identification and localisation of small bowel Crohn’s 
disease, irrespective of activity—ie, the extent of small 
bowel disease. To be truly positive for disease extent, the 
index test had to correctly locate the presence and 
segmental location of disease (terminal ileum, ileum, 
jejunum, or duodenum). Secondary outcomes reported 
here were specificity for disease extent, sensitivity and 
specificity for small bowel disease presence, the 
difference in per patient sensitivity and specificity for 
colonic disease presence and extent, and identification of 
active disease and comparative patient experience. 
Secondary outcomes also included comparative impact 
of MRE and ultrasound on clinician diagnostic 
confidence for presence of Crohn’s disease and their 
influence on management, cost-effectiveness of MRE 
and ultrasound (compared to each other), diagnostic 
impact of novel MRE sequences (eg, diffusion-weighted 
imaging), influence of sequence selection on MRE 
diagnostic accuracy, diagnostic accuracy of small 
intestine contrast enhanced ultrasonography (SICUS) 
compared with standard ultrasound, influence of oral 
contrast agent and ingested volume on small bowel 
distension and patient experience during MRE, and 
interobserver variation, which will be reported elsewhere. 
We reported most outcomes for the newly diagnosed 
and suspected luminal relapse groups individually, and 
for the terminal ileum and colon using colonoscopy as a 
standalone reference standard (when available) because 
of its robustness for identifying disease.
We prespecified all outcomes in the protocol24 except 
accuracy for individual small bowel segments (duo-
denum, jejunum, ileum), accuracy for disease presence 
and extent in the colon, and per-patient disease activity 
518 screened participants 
183 excluded
 58 declined participation
 28 failed to respond to invitation
 22 diagnosis other than Crohn’s disease
 20 unable to complete MRE or ultrasound in timely fashion
 13 did not meet trial eligibility criteria (relapse cohort) based on 
  low CRP
 8 contraindication to MRE
 7 not able give informed consent
 5 previous recruitment or declined approach
 4 moved or lived far away
 4 proceeded straight to surgery before colonoscopy (new 
  diagnosis cohort)
 2 newly diagnosed >3 months previously
 2 <16 years old
 10 unknown
335 recruited participants 
51 withdrawals
 31 final diagnoses other than Crohn’s disease
 5 did not have MRE
 3 did not have ultrasound
 2 did not have MRE or ultrasound 
 3 withdrew consent
 3 no longer wished to participate in follow-up
 2 lost to follow-up
 2 had surgery without colonoscopy
284 included participants 
133 newly diagnosed participants
Index tests
133 MRE and ultrasound 
Reference standard
133 consensus panel at 6 months
Index tests
151 MRE and ultrasound 
Reference standard
151 consensus panel at 6 months
151 suspected relapse participants
Figure 1: Trial profile
CRP=C-reactive protein. MRE=magnetic resonance enterography. 
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(small bowel and colonic disease combined), which were 
exploratory.
Safety reporting was limited to any suspected 
unexpected serious adverse reaction directly related to 
MRE, ultrasound, or any arbiter small bowel imaging 
test. Expected adverse reactions, such as contrast agent 
allergy, were not collated.
Statistical analysis
We estimated that a sample size of 210 patients with small 
bowel disease would give 90% power to detect a clinically 
significant (10%) sensitivity difference for small bowel 
disease extent between MRE (83%, based on a sensitivity 
of 93% for disease presence and 90% for disease location) 
and ultrasound (73%, based on a sensitivity of 88% for 
disease presence and 83% for disease location), assuming 
68% positivity for both tests and using methods for 
comparative studies.24,26 A 10% difference in sensitivity 
was deemed to be  clinically meaningful in routine 
practice by the study investigators  at the time of trial 
design. We assumed a 70% prevalence of small bowel 
disease and 10% loss to follow-up or diagnosis with a 
disease other than Crohn’s disease, which gave a target 
sample size of 334 patients across both groups (167 in the 
newly diagnosed group and 167 in the relapse group). 
The trial was not powered to detect differences between 
the groups, or between bowel segments.
We treated disease reported as equivocal as positive in 
the analysis. We calculated the primary outcome per 
patient. We based the secondary outcomes for bowel 
segments on all segments, excluding those resected at 
baseline (neoterminal ileum was considered as the 
terminal ileum). 
We calculated a direct comparison of sensitivity and 
specificity differences between MRE and ultrasound 
using bivariate, multilevel, patient-specific (conditional), 
random-effects models, from paired data using meqrlogit 
in STATA 14.2 (College Station, TX, USA). When models 
did not converge due to small numbers of patients, we 
used McNemar’s comparison of paired proportions to 
obtain univariable estimates and we calculated exact 
95% CI. We did analysis by segment using a population-
averaged, random-effects model (using logit, including 
robust standard errors). We based statistical significance 
on 95% CI. 
This trial is registered with the International Standard 
Randomised Controlled Trial, number ISRCTN03982913.
Role of the funding source 
The funder (the National Institute for Health Research) 
stipulated a diagnostic accuracy trial using a cohort 
design but were not involved in the collection, analysis, 
or interpretation of data, or in the writing or submitting 
of this report. The corresponding author had full access 
to all data and final responsibility for the decision to 
submit for publication.
Results 
We commenced recruitment on Dec 4, 2013, and 
completed it on Sept 30, 2016. Overall, we assessed 
518 patients for eligibility, of whom 183 were excluded 
(figure 1). Of the 335 patients who entered the trial, 
51 were subsequently excluded (20 men, median 30 years 
[IQR 24–41]); 31 did not have Crohn’s disease, two were 
lost to follow-up, ten did not have MRE or ultrasound or 
both, six withdrew consent or no longer wished to 
participate in follow-up, and two newly diagnosed patients 
had surgery without colonoscopy. With a final group 
New diagnosis 
(n=133)
Relapse (n=151)
Sex
Male 69 (52%) 61 (40%)
Female 64 (48%) 90 (60%)
Age (years)
16–25 49 (37%) 46 (30%)
26–35 32 (24%) 36 (24%)
36–45 18 (14%) 28 (19%)
>45 34 (26%) 41 (27%)
Disease duration (years)
<1 NA 5 (3%)
1–5 NA 45 (30%)
6–10 NA 39 (26%)
>10 NA 62 (41%)
Disease location (Montreal classification)*
L1 NA 56 (37%)
L2 NA 17 (11%)
L3 NA 74 (49%)
L4 NA 4 (3%)
Disease behaviour (Montreal classification)*
B1 NA 80 (53%)
B1p NA 4 (3%)
B2 NA 52 (34%)
B2p NA 1 (1%)
B3 NA 12 (8%)
B3p NA 2 (1%)
Medication†
None 62 (47%) 32 (21%)
Mesalazine 21 (16%) 26 (17%)
Steroids 48 (36%) 28 (19%)
Immunomodulators 16 (12%) 75 (50%)
Anti-TNF antibodies 5 (4%) 42 (28%)
Previous enteric resection 1 (1%)‡ 72 (48%)
Data are n (%). TNF=tumour necrosis factor. NA=not applicable. *Montreal 
classification not collected for patients in the new diagnosis group. †Patients 
could take more than one type of medication. ‡Surgical resection for 
inflammatory mass 1 year before Crohn’s disease diagnosis. 
Table 1: Patient demographics
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of 284, 133 were included in the newly diagnosed group 
and 151 in the relapse group (figure 1; table 1), including 
154 (54%) women. Based on the reference standard, 
233 (82%) of 284 patients had small bowel Crohn’s disease 
(thereby meeting sample size stipulations), which was 
active in 209 (90%) patients (table 2). 129 (45%) of 
284 patients had colonic disease, which was active in 
126 (98%) patients. No data were missing for per-patient 
diagnosis of disease presence or disease extent, for the 
reference standard, MRE, or ultrasound. 
In 53 patients (24 from the newly diagnosed group 
and 29 from the relapse group), MRE and ultrasound 
were discrepant for small bowel disease presence or 
location, of whom 48 (91%) patients had an additional 
small bowel imaging test available to the consensus 
panel. The range of imaging, endoscopic, and bio-
chemical data available to the consensus panels is 
shown in the appendix (p 5). 
The sensitivity of MRE for the extent of small bowel 
disease (ie, presence and correct segmental location) 
was 80% (95% CI 72–86) compared with 70% (62–78) 
for ultrasound, a significant difference of 10% (1–18; 
p=0·027; table 3; appendix p 6). The specificity of 
MRE for the extent of small bowel disease was also 
significantly greater (95% [85–98]) than that of ultra-
sound (81% [64–91]), with a difference of 14% (1–27; 
p=0·039). 
The sensitivity of MRE (97% [95% CI 91–99]) for the 
presence of small bowel disease, regardless of location, 
was significantly greater than that of ultrasound (92% 
[84–96]), with a difference of 5% (1–9; table 3; figure 2). 
The sensitivities of MRE and ultrasound for small bowel 
disease presence and extent in the newly diagnosed group 
and relapsed group were very similar to those estimated 
across all patients (table 4). However, ultrasound (67% 
[95% CI 49–81]) had significantly greater sensitivity for 
colonic disease presence than MRE (47% [31–64]) in the 
newly diagnosed patient group, with a difference of 20% 
(1–39). MRE and ultrasound had no significant difference 
in sensitivity or specificity for the extent and presence of 
colonic disease (table 3; figure 2). For both tests, sensitivity 
for colonic disease tended to be higher in the relapsed 
group than the newly diagnosed group (table 4), although 
the estimated sensitivity for colonic disease extent was 
poor for both groups.
The detection rate for individual small bowel and 
colonic segments is given in the appendix (p 7). Although 
the trial was not powered to detect differences on a 
segmental level, MRE was significantly more sensitive 
than ultrasound for ileal (84% [95% CI 67–93] vs 56% 
[38–73]) and rectal disease (44% [32–58] vs 22% [13–35]).
The sensitivity of MRE for active small bowel disease 
was 96% (95% CI 92–99) compared with 90% (82–95) for 
ultrasound, a significant difference of 6% (2–11; table 5). 
The specificity for active small bowel disease and for 
active colonic disease were not significantly different 
between tests (table 5). The sensitivity and specificity for 
active disease split by patient group were very similar to 
those estimated across all patients (appendix p 8).
21 patients had enteric fistulae, and seven patients had 
intra-abdominal abscess. MRE detected five (71%) of 
seven abscesses, whereas ultrasound detected three 
(43%) of seven abscesses. MRE detected 18 (86%) of 
21 patients with enteric fistulae compared with 11 (52%) 
of 21 patients for ultrasound.  
Against a colonoscopic standard of reference (available 
in 186 patients), MRE had a sensitivity of 97% (95% CI 
91–99) for terminal ileal disease presence compared with 
a sensitivity of 91% (79–97) for ultrasound, a difference of 
6% (–1 to 12; appendix p 9). The sensitivity for colonic 
disease presence was modest for both MRE (41% [26–58]) 
and ultrasound (49% [33–65]) and was not statistically 
different.
Of responding patients, 128 (88%) of 145 patients rated 
MRE as acceptable and 144 (99%) of 146 patients rated 
ultrasound as acceptable. Diagnostic accuracy was rated as 
the most important test attribute. 
No serious adverse events or any other adverse events 
were reported. 
Discussion 
In the METRIC trial, we found that both MRE and 
ultrasound were highly accurate for detecting small 
bowel Crohn’s disease, achieving 97% sensitivity for 
New diagnosis 
(n=133)
Suspected relapse 
(n=151)
Full cohort 
(n=284)
Disease presence
Small bowel disease present 111 (83%) 122 (81%) 233 (82%)
Colonic disease present 77 (58%) 52 (34%) 129 (45%)
Isolated small bowel disease present 56 (42%) 85 (56%) 141 (50%)
Isolated colonic disease present 22 (17%) 15 (10%) 37 (13%)
Both small bowel and colonic disease present 55 (41%) 37 (25%) 92 (32%)
Total number of patients with disease present 133 (100%) 137 (91%) 270 (95%)
Median number of involved small bowel 
segments, median (IQR), maximum
1 (1–1), 4 1 (1–1), 3 1 (1–1), 4
Median number of involved colonic segments, 
median (IQR), maximum
1 (0–3), 6 0 (0–1), 6 0 (0–2), 6
Disease activity
Small bowel disease active 104 (94%) 105 (86%) 209 (90%)
Colonic disease active 76 (99%) 50 (96%) 126 (98%)
Total number of patients with disease active 130 (98%) 121 (88%) 251 (93%)
Criteria for activity* 
Ulceration at endoscopy 71 (55%) 26 (21%) 97 (39%)
CRP >8 mg/L 47 (36%) 57 (47%) 104 (41%)
Calprotectin >250 g/g 41 (32%) 43 (36%) 84 (33%)
Histological evidence of activity 100 (77%) 36 (30%) 136 (54%)
Data are n (%), unless otherwise specified. CRP=C-reactive protein. *Patients could meet more than one criteria for 
disease activity. 
Table 2: Disease presence and activity based on the consensus reference standard 
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MRE and 92% sensitivity for ultrasound. Barium 
fluoroscopy has long been advocated as a sensitive test 
for mucosal disease inaccessible to endoscopy, although 
its support is limited to a handful of small studies2 and 
its accuracy is increasingly questioned.27 Conversely, 
against a rigorous ileocolonoscopic reference standard, 
we found that MRE and ultrasound achieved 97% and 
91% sensitivity for terminal ileal disease, strongly 
supporting their transition to first-line investigations, 
and positioning them as competitive and viable 
diagnostic alternatives to invasive ileocolonoscopy. Of 
the two, we found MRE had significantly higher 
sensitivity and specificity than ultrasound for small 
bowel extent, and higher sensitivity for disease presence. 
Overall, no significant difference was found in diagnostic 
accuracy for colonic disease (consistently lower than for 
small bowel disease), although ultrasound had greater 
sensitivity than MRE in newly diagnosed patients. To 
our knowledge, the METRIC trial is the largest 
prospective multicentre trial to date directly comparing 
diagnostic accuracy of MRE and ultrasound for the 
presence, extent, and activity of Crohn’s disease in the 
same patients.
Our primary outcome combined those aspects 
necessary to stage small bowel Crohn’s disease correctly—
ie, is disease present, and, if so, where? Both presence 
and extent dictate subsequent therapeutic strategy. For 
example, the finding of additional proximal small bowel 
disease might tip the balance towards medical rather than 
surgical intervention in the face of otherwise isolated 
terminal ileal disease. As expected, sensitivity for disease 
extent was lower than that for disease detection alone. 
Our detection rates were at the upper end of estimates 
from previous meta-analyses.6,9–20 Dong and colleagues12 
estimated ultrasound to have a sensitivity 88% and a 
specificity of 97%; Liu and colleagues17 reported corre-
sponding figures of 86% sensitivity and 93% specificity for 
MRE. However, the primary literature is markedly 
heterogeneous, which affects the validity of point 
estimates. Most studies were single centre and typically 
recruited fewer than 50 patients, and many were methodo-
logically poor.17,21 Direct comparison of dia gnostic tests in 
Sensitivity Specificity 
Number 
of disease 
positive*
MRE Ultrasound Difference p value Number 
disease 
negative*
MRE Ultrasound Difference p value
Small bowel disease extent† 233 80% (72 to 86) 70% (62 to 78) 10% (1 to 18) 0·027 51 95% (85 to 98) 81% (64 to 91) 14% (1 to 27) 0·039
Small bowel disease presence 233 97% (91 to 99) 92% (84 to 96) 5% (1 to 9) 0·025 51 96% (86 to 99) 84% (65 to 94) 12% (0 to 25) 0·054
Colonic disease extent† 129 22% (14 to 32) 17% (10 to 27) 5% (–5 to 15) 0·332 155 93% (87 to 97) 93% (87 to 97) 0% (–5 to 5) 1·000
Colonic disease presence 129 64% (50 to 75) 73% (59 to 83) –9% (–23 to 5) 0·202 155 96% (90 to 98) 96% (90 to 98) 0% (–3 to 3) 1·000
Small bowel and colonic disease 
extent†
270 44% (36 to 54) 29% (21 to 38) 16% (6 to 25) 0·002 14 80% (42 to 96) 61% (23 to 89) 19% (–20 to 59) 0·337
Small bowel and colonic disease 
presence‡
270 78% (70 to 85) 71% (62 to 79) 7% (–2 to 15) 0·117 14 80% (42 to 96) 61% (23 to 89) 19% (–20 to 59) 0·335
Data are n, % (95% CI), or p value. MRE=magnetic resonance enterography. *Patients by consensus reference standard. †Agreement with reference standard for disease presence and segmental location. 
‡Agreement with reference standard for disease presence (patients with disease in the small bowel, colon, or both). 
Table 3: Per-patient sensitivity and specificity for disease presence and extent against the consensus reference standard for patient groups combined
Specificity (95% CI)Test
Small bowel disease extent
MRE
Ultrasound
Small bowel disease presence
MRE
Ultrasound
Colonic disease extent
MRE
Ultrasound
Colonic disease presence
MRE
Ultrasound
TP FN FP TN
 171
152
 62
81
 5
13
 46
38
 210
193
 23
40
 5
13
 46
38
 35
29
 94
100
 17
 17
 138
138
 76
84
 53
45
 17
17
 138
138
95% (85–98)
81% (64–91)
Sensitivity (95% CI)
80% (72–86)
70% (62–78)
96% (86–99)
84% (65–94)
97% (91–99)
92% (84–96)
93% (87–97)
93% (87–97)
22% (14–32)
17% (10–27)
96% (90–98)
96% (90–98)
64% (50–75)
73% (59–83)
40200 80 10065
Sensitivity
40200 80 10065
Specificity
Figure 2: Sensitivity and specificity of MRE and ultrasound for the extent and presence of small bowel and colonic disease against the consensus reference 
standard
FN=false negative. FP=false positive. MRE=magnetic resonance enterography. TN=true negative. TP=true positive. Error bars represent 95% CI.
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the same patients is advocated as the optimal method for 
diagnostic accuracy studies22 because differences are 
attributable directly to the tests and not to differences 
between participants or study methods. Such head-to-head 
comparisons are rare in the medical literature.15 Reference 
standards might also be applied inconsistently, with 
endoscopy, surgery, and imaging all variably employed. 
For example, in a comparative study with ultrasound, 
Castiglione and colleagues28 used MRE without any 
additional reference standard in many recruits, which 
introduces the potential for incorporation bias. 
We used the construct reference standard model (panel 
diagnosis), which incorporates multiple data sources with 
clinical outcome.23 Although such an approach does have 
limitations, including potential panel bias, it is considered 
a very robust method for diagnostic accuracy studies in 
which a single external reference standard is elusive.23 To 
reduce incorporation bias, patients without supplementary 
small bowel imaging had a third small bowel investigation 
whenever discrepancy between MRE and ultrasound 
arose. Notably, when our analysis was limited to an 
ileocolonoscopic reference standard, any differences in 
accuracy between MRE and ultrasound closely mirrored 
those found using the consensus panel reference.
We recruited approximately equally from two patient 
groups: newly diagnosed Crohn’s disease and established 
disease with relapse. Both groups are clinically distinct and 
important, and might manifest with differing disease 
phenotypes; prevalence of stricturing and penetrating 
disease increases with time.29 Noting that the METRIC trial 
was not powered to detect differences between these two 
patient groups, we found that sensitivity for small bowel 
disease was similar, although specificity tended to be lower 
in patients in the relapse group. Conversely, sensitivity for 
colonic disease was higher in the relapse group, but was 
still poor for colonic disease extent (about 30%).
In newly diagnosed patients, ultrasound achieved 
significantly greater sensitivity for colonic disease than 
MRE (67% vs 47%). Optimised colonic assessment with 
MRE requires purgation and fluid distension,30 which are 
both omitted from routine MRE protocols; however, 
ultrasound generally relies on assessing the manually 
compressed uncleansed colon wall. Accuracy for both 
techniques in the colon still falls short of colonoscopy, 
and accuracy with MRE is somewhat lower than 
previously reported.31,32 By way of explanation, ileo colon-
oscopy and histopathology results were available to the 
consensus reference panel for most patients (particularly 
those newly diagnosed) and are exquisitely sensitive for 
early mucosal disease, beyond the resolution of cross-
sectional imaging. Our outcomes were dependent on 
disease presence regardless of severity. Previous single-
centre explanatory studies either use groups enriched 
with more advanced colonic disease,32 or report sensitivity 
for deep rather than superficial mucosal disease.31
Most patients found MRE and ultrasound acceptable, 
although slightly more found ultrasound acceptable. This 
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outcome is perhaps expected given the different attributes 
of the two tests. However, patients rated diagnostic 
accuracy as the most important test attribute, consistent 
with previous work,33 suggesting patients will tolerate 
greater discomfort for improved test performance. 
The METRIC trial does have some limitations. It was 
conceived as a large pragmatic trial34 since the medical 
literature is replete with small explanatory studies. We 
recruited from a range of hospital settings, both teaching 
and district general, and used local imaging protocols to 
enhance generalisability. The 28 practitioners all declared 
a specialist interest in gastrointestinal radiology and were 
representative of those reporting NHS small bowel 
imaging in terms of training and experience. We 
specifically avoided using a small number of highly 
experienced practitioners since they would not represent 
a national workforce. However, we acknowledge that 
specialist practitioners working in high volume practices 
might achieve sensitivities in excess of our findings. 
Imaging was interpreted according to local clinical practice 
to mirror real-world procedures within the NHS and 
enhance generalisability of our results. We acknowledge 
that masking practitioners to individual patient history 
does not mirror usual clinical practice, but this precaution 
was necessary to isolate diagnostic test accuracy as far as 
possible. We cannot, however, exclude occasional inad-
vertent unmasking of reporting practitioners. Recruited 
patients were representative of those having MRE and 
ultrasound in daily practice, although we did exclude 
pregnant women, patients having routine therapeutic 
response assessment, and patients with contraindications 
to MRI. Our results are therefore highly likely to be 
extrapolable across the NHS and similar health-care 
settings. The prevalence of active disease was predictably 
high given our recruited patient groups. Therefore, the 
reported high specificity of MRE and ultrasound should be 
viewed in this context.
We did not standardise the third small bowel 
investigation whenever discrepancy between MRE and 
ultrasound arose, and this decision was left to the 
discretion of the recruitment site. Direct mucosal 
visualisation is possible with push enteroscopy35 or 
capsule endoscopy,36 but to insist on such investigations 
was not practicable in the setting of a pragmatic 
multicentre trial given their cost, relatively inadequate 
availability, and probable negative effect on patient 
compliance and safety. Push enteroscopy, for example, is 
a highly invasive and specialised investigation, and 
attracts a small but well documented risk of major 
complications, such as perforation.37 Similarly the risk of 
capsule retention is around 8% in patients with known 
Crohn’s disease38 and specificity is questioned.39 We also 
considered that the invasive nature of capsule endoscopy 
or enteroscopy would result in considerable spectrum 
bias relating to differences between patients who would 
and would not agree to consent (even if they were 
available and affordable).
To reduce incorporation bias from MRE or ultrasound, 
we required at least one independent biochemical, 
endoscopic, or histological marker of disease activity 
before a patient could be diagnosed with active small 
bowel or colonic disease. Biochemical markers, such 
as calprotectin and CRP concentrations, provide evidence 
at the patient level, but the reference standard consensus 
panel also had access to a range of additional clinical 
material when making their decision, including endo-
scopy and a range of small bowel imaging investi gations. 
Some data suggest that the diagnostic accuracy of 
ultrasound can be improved with an oral contrast load 
(SICUS), particularly for luminal stenosis, and 
intravenous contrast enhanced ultrasound (CEUS) 
might have utility for assessing disease activity.40 
However, neither SICUS nor CEUS have disseminated 
as first-line investigations outside specialist units, and 
if used are often employed as problem solving tools.40,41 
Standard ultrasound is overwhelmingly the most 
commonly used technique in routine clinical practice. 
Future prospective research could consider inclusion of 
SICUS and CEUS in trial design.
Diagnostic accuracy is clearly paramount when patients 
are investigated, but interobserver variability and cost- 
effectiveness are also of great importance and will be 
reported elsewhere, together with a more detailed 
consideration of patient experience.
In summary, we found that both ultrasound and MRE 
achieve excellent diagnostic accuracy for the extent and 
Sensitivity Specificity 
Patients 
with active 
disease*
MRE Ultrasound Difference p value Patients 
with inactive 
disease*
MRE Ultrasound Difference p value
Active small bowel disease† 209 96% (92 to 99) 90% (82 to 95) 6% (2 to 11) 0·010 75 83% (68 to 92) 77% (60 to 88) 6% (–8 to 20) 0·376
Active colonic disease† 126 63% (48 to 76) 66% (51 to 79) –3% (–18 to 13) 0·735 158 97% (91 to 99) 98% (94 to 99) –1% (–4 to 1) 0·304
Active small bowel and 
colonic disease‡
251 77% (68 to 85) 66% (56 to 75) 11% (1 to 21) 0·024 33 28% (10 to 56) 28% (10 to 56) 0% (–26 to 26) 1·000
Data are n, % (95% CI), or p value. MRE=magnetic resonance enterography. *Patients by consensus reference standard. †Agreement with reference standard for disease active. ‡Agreement with reference 
standard for active disease presence (patients with disease in the small bowel, colon, or both). 
Table 5: Per-patient sensitivity and specificity for the presence of active disease versus the consensus reference standard for patient groups combined
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activity of small bowel Crohn’s disease in newly 
diagnosed patients and those who have relapsed, and 
both tests are valid firstline investigations. In an NHS 
setting, MRE is generally the preferred radiological 
investigation when available because its sensitivity and 
specificity exceed ultrasound significantly. 
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